Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Diagnostics & Research

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.

Revenue projections:

Revenue projections for DHR
Revenue projections for DHR

DHR's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.

Financial Ratios:

currentRatio 1.868000
forwardPE 19.681316
debtToEquity 37.170000
earningsGrowth 0.098000
revenueGrowth 0.037000
grossMargins 0.589920
operatingMargins 0.229370
trailingEps 5.150000
forwardEps 9.092380

The current ratio for DHR is 1.868, indicating that the company can service its short-term debt using available cash and assets. This suggests DHR has strong liquidity, with more than enough resources to meet its immediate financial commitments.
DHR's Forward PE is in a favorable range, meaning its stock price compares well with its earnings and isn't overpriced. This leaves room for growth, making it a compelling opportunity for investors looking to benefit from potential future gains.
DHR's positive gross and operating margins indicate that the company is performing profitably. These margins reflect efficient cost control and revenue generation, signaling a strong financial foundation for continued success.
DHR's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that DHR's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for DHR
Price projections for DHR

DHR's price projections have been revised downward gradually, suggesting that expectations for the company's future performance are becoming more conservative. Analysts may be tempering their optimism based on current trends.

Insider Transactions:

Insider Transactions for DHR
Insider Transactions for DHR


10 separate sales of DHR shares were executed, with the market price hovering at 214.1229995727539.No sell transactions occurred in the period under review.The recent trend of more purchases than sales at Danaher Corporation's current price could signal investor optimism. This pattern may point to a positive outlook for the stock, as it indicates growing confidence in its potential to perform well in the future.

Recommendation changes over time:

Recommendations trend for DHR
Recommendations trend for DHR


Analysts are favoring Danaher Corporation with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider Danaher Corporation as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.